KR20240153603A - Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법 - Google Patents

Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법 Download PDF

Info

Publication number
KR20240153603A
KR20240153603A KR1020247032991A KR20247032991A KR20240153603A KR 20240153603 A KR20240153603 A KR 20240153603A KR 1020247032991 A KR1020247032991 A KR 1020247032991A KR 20247032991 A KR20247032991 A KR 20247032991A KR 20240153603 A KR20240153603 A KR 20240153603A
Authority
KR
South Korea
Prior art keywords
antigen
amino acid
bispecific antibody
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032991A
Other languages
English (en)
Korean (ko)
Inventor
대니얼 제이. 프리먼
수양 송
셸비 가이너
디파 수브라마니암
이크벨 아슈르
찰스 페르테
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20240153603A publication Critical patent/KR20240153603A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247032991A 2022-03-07 2023-03-06 Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법 Pending KR20240153603A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263317200P 2022-03-07 2022-03-07
US63/317,200 2022-03-07
US202263347748P 2022-06-01 2022-06-01
US63/347,748 2022-06-01
US202263374815P 2022-09-07 2022-09-07
US63/374,815 2022-09-07
PCT/IB2023/052086 WO2023170549A1 (en) 2022-03-07 2023-03-06 Treatment methods using ctla-4 and pd-1 bispecific antibodies

Publications (1)

Publication Number Publication Date
KR20240153603A true KR20240153603A (ko) 2024-10-23

Family

ID=87936206

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032991A Pending KR20240153603A (ko) 2022-03-07 2023-03-06 Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법

Country Status (9)

Country Link
US (1) US20230322928A1 (https=)
EP (1) EP4489781A4 (https=)
JP (1) JP2025508024A (https=)
KR (1) KR20240153603A (https=)
AU (1) AU2023231766A1 (https=)
CA (1) CA3253514A1 (https=)
IL (1) IL315307A (https=)
TW (1) TW202400656A (https=)
WO (1) WO2023170549A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
IL260021B (en) * 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
WO2021023117A1 (zh) * 2019-08-02 2021-02-11 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体及其用途
WO2023015292A1 (en) * 2021-08-06 2023-02-09 Xencor, Inc. Prostate cancer treatment or treatment of gynecologic or genitourinary malignancy with a bispecific antibody that binds ctla4 and pd1
TW202348788A (zh) * 2022-04-01 2023-12-16 美商藝康美國公司 協同防汙劑組成物及使用其之方法

Also Published As

Publication number Publication date
US20230322928A1 (en) 2023-10-12
WO2023170549A1 (en) 2023-09-14
JP2025508024A (ja) 2025-03-21
AU2023231766A1 (en) 2024-10-17
TW202400656A (zh) 2024-01-01
IL315307A (en) 2024-10-01
CA3253514A1 (en) 2023-09-14
EP4489781A4 (en) 2026-03-25
EP4489781A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
EP3866850B1 (en) Combination therapy for melanoma
JP2022068352A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
CN106456764A (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
KR20190015407A (ko) 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
KR20200108868A (ko) 암을 치료하기 위한 항-il-8 항체 및 항-pd-1 항체와의 조합 요법
JP2025118688A (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
JP2022500410A (ja) 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ−１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ
JP7258038B2 (ja) Ｂ７－ｈ４抗体の投薬計画
JP2024514590A (ja) Ｐｄ－１及びｔｉｍ－３を標的化する二重特異性抗体
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
JP2023551980A (ja) 抗体およびタキソンの併用療法
US20230322928A1 (en) Treatment methods using ctla-4 and pd-1 bispecific antibodies
JP2019534303A (ja) 非小細胞肺がんを治療するための抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体
US20240190961A1 (en) Combination of anti-garp antibody and immunomodulator
HK40117614A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
WO2026061422A1 (en) Methods for treating cancer
KR20260013484A (ko) 암 치료에서 t 세포 인게이징 단백질의 용도
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
CA3190934A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241002

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application